RED-WING-SHOE
10.4.2018 11:17:05 CEST | Business Wire | Press release
Today, Red Wing announced its PetroKing line of work boots, purpose-built for the global energy industry. Lightweight and flexible, PetroKing revolutionizes industrial footwear by combining innovative safety features and comfort. It includes styles that deliver advanced, 360-degree protection from the top of the foot to the heel and ankle for maximum performance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180410005651/en/
In the energy industry, workers are often subject to long hours on their feet in the harshest conditions. Built from the ground up, both the PetroKing XT and LT lines are constructed by bonding the upper directly to the sole for an agile boot that offers stability on uneven surfaces. The high-quality foot bed and outsole system offers shock absorption, breathability, sole puncture resistance and four layers of cushioning. Utilizing premium, fiberglass-composite toe caps along with a primarily metal-free package makes PetroKing rugged and comfortable without the weight and bulk.
“We strategically built PetroKing by listening to our customers in the energy sector and designing a boot line to not only meet but exceed their expectations,” said Glenn Bingen, international product line manager at Red Wing Shoe Company. “Our product development and customer support teams know these workers operate in the most extreme and demanding conditions, and it was our goal to enable their productivity, comfort and most of all safety with a stand-out footwear solution.”
PetroKing features 16 styles to meet the needs of almost every job in the energy industry. For example, the PetroKing XT includes an oxford style, 8-inch side zip boot and an 8-inch boot incorporating Boa® lacing for getting in and out fast and easy. In addition, the 11-inch pull-on boot has a FLEXGRIP™ panel that grips around the ankle, expanding to allow the heel to easily enter and exit and contracting for a tight, comfortable fit with superior ankle support for the stability needed in more challenging work settings.
Additional features include:
- Patented D3O® impact protection technology for exceptional defense from harmful drops. Incorporated around the ankle and metatarsal, D3O® material instantly absorbs and dissipates forces that come in contact with the boot to retain flexibility. Incorporated in all PetroKing XT styles, the soft, lightweight material is waterproof and temperature-stable for on-the-job comfort.
- TredMax rubber outsole for best slip-resistant technology for wet and oily environments, including perimeter lugs for traction on angled surfaces. PetroKing XT and LT styles offer electrical hazard (EH) and static-dissipative (SD) options to meet job-specific needs.
All Red Wing products undergo in-house laboratory testing, in addition to third-party testing and field testing in extreme work environments to ensure they pass or surpass global safety standards including EN ISO and ASTM. Red Wing offers complete head-to-toe protection for energy companies worldwide through its assortment of personal protective equipment (PPE) offerings. That not only incudes its renowned work boots like PetroKing, but flame-resistant workwear, gloves, safety glasses and other high-performance gear.
Safety professionals, procurement officers and workers who are interested in learning more about PetroKing or other Red Wing products can visit http://www.redwingsafety.com/petroking .
About Red Wing Shoe Company
Red Wing Shoe Company, Inc. is a global leader in the design, production and distribution of work, safety and lifestyle footwear and work apparel. Established in 1905 in Red Wing, Minn., today the privately held company’s family of brands includes Red Wing®, the premium choice for purpose-built work footwear, workwear and accessories including a collection of Heritage styles created for any occasion; Irish Setter®, the footwear brand of choice for hunters and workers who want uncompromising quality and technological innovation; Vasque®, a pioneer of performance hiking footwear; WORX™, a trusted brand for the industrial safety footwear market; and S.B. Foot Tanning Company, one of the largest U.S. producers of fine tanned leather for footwear and leather goods. Its brands are distributed to more than 110 countries in an immersive multi-channel environment of 500+ Red Wing retail stores, third-party partners, and owned ecommerce platforms. Red Wing Shoe Company employs more than 2,000 employees worldwide today, and operates two U.S. manufacturing facilities in Red Wing and Potosi, Mo. For more information, please visit redwingshoes.com, facebook.com/RedWingShoes or follow @RedWingShoes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180410005651/en/
Contact:
Kohnstamm Communications
Luke Gillespie, 651-228-9141
luke@kohnstamm.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom